Inhaled TB vaccine

Study shows promising results

USA - A new tuberculosis vaccine successfully tested at the University of North Carolina (UNC) is easier to administer and store and just as effective as one commonly used worldwide, according to research published in the Proceedings of the National Academy of Sciences.

Led by Professor Tony Hickey PhD, of the molecular pharmaceuticals division of the UNC School of Pharmacy, a team of scientists vetted a dry powder vaccine provided by Harvard University. This is administered using an inhaler. ‘It is at least as good as the injectable vaccine,’ Prof. Hickey concluded. ‘The real advantage is that this vaccine does not need to be refrigerated. It also doesn’t require needles, syringes and water like the injectable vaccine. Administering it is as easy as breathing in, making it ideal for use in developing countries.’
The vaccine is spray dried instead of freeze dried. Spray drying is the process of spraying a liquid through a heated gas, such as nitrogen, to create a powder. Traditional TB vaccines are freeze dried, requiring refrigerated storage and transportation, and a source of clean water to reconstitute the vaccine for injection. Spray dried vaccines do not need refrigeration or water before use.
Prof. Hickey’s group specialises in developing drugs and vaccines that can be inhaled as a dry powder. The vaccine used in the study was a Bacillus Calmette-Guérin (BCG) vaccine, which is not common in the USA but is used extensively throughout the world. Given to 100 million infants annually, the current BCG vaccine for TB is the world’s most widely administered childhood vaccine.
As an expert on the delivery of vaccines and medicines via dry aerosol, Prof. Hickey said that breathing in a TB vaccine is beneficial because inhalation is the way TB is contracted. He also believes this successful vaccine test could encourage the development of others. ‘Other bacterial vaccines are being developed that might benefit from this technology,’ he said.
Prof. Hickey is a co-founder of Oriel Therapeutics, a company that develops dry-powder inhaler products to deliver medicines effectively to the lungs to treat a wide range of respiratory diseases, such as asthma and chronic obstructive pulmonary disease. He is also the founder, president and CEO of Cirrus Pharmaceuticals – both based in North Carolina.
Study co-authors: UNC School of Pharmacy research assistant professor Lucila Garcia-Contreras PhD, and postdoctoral fellows Pavan Muttil and Danielle Padilla.
E-contact: ahickey@unc.edu.School of Pharmacy contact: David Etchison. david_etchison@unc.edu

30.04.2008

More on the subject:
Read all latest stories

Related articles

Photo

Aducanumab

FDA grants accelerated approval for Alzheimers drug

The U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the…

Photo

Fighting the pandemic

90 drugs against Covid-19

Mining the world's most comprehensive drug repurposing collection for Covid-19 therapies, scientists have identified 90 existing drugs or drug candidates with antiviral activity against the…

Photo

Drug repurposing

Social impact bonds leverage private investment

Identifying new uses for approved therapeutic drugs continues to drive academics and clinicians to provide safe, affordable and rapid development of new treatment options for patients with common or…

Subscribe to Newsletter